Aubagio

E561778

Aubagio is a prescription oral medication (teriflunomide) used to treat relapsing forms of multiple sclerosis in adults.

Try in SPARQL Jump to: Statements Referenced by

Statements (48)

Predicate Object
instanceOf brand name drug
disease-modifying therapy for multiple sclerosis
pharmaceutical drug
hasActiveIngredient teriflunomide NERFINISHED
hasATCCode L04AA31
hasBlackBoxWarning embryo-fetal toxicity
hepatotoxicity
hasBoxedWarningRegion United States NERFINISHED
hasDosageForm oral tablet
hasEffect reduces relapse rate in relapsing multiple sclerosis
slows accumulation of physical disability in multiple sclerosis
hasEliminationProcedure activated charcoal washout
cholestyramine washout
hasGenericName teriflunomide NERFINISHED
hasIndicationPopulation adults
hasLongHalfLife true
hasPharmacologicClass immunomodulator
pyrimidine synthesis inhibitor
hasPregnancyCategory contraindicated
hasRegulatoryAgencyApproval European Medicines Agency NERFINISHED
U.S. Food and Drug Administration NERFINISHED
hasRisk infections due to immunosuppression
serious liver injury
serious skin reactions
hasRouteOfAdministration oral
hasRouteOfElimination hepatic
hasTeratogenicRisk true
isAdministeredOnceDaily true
isContraindicatedIn pregnancy
severe hepatic impairment
isMarketedBy Sanofi NERFINISHED
isMetabolizedIn liver
isPrescriptionDrug true
isTakenWithFood may be taken with or without food
isUsedFor active secondary progressive multiple sclerosis
clinically isolated syndrome (CIS)
relapsing forms of multiple sclerosis
relapsing-remitting multiple sclerosis
mayCause alopecia (hair thinning)
diarrhea
elevated liver enzymes
hypertension
nausea
peripheral neuropathy
mechanismOfAction inhibits dihydroorotate dehydrogenase (DHODH)
reduces proliferation of activated T and B lymphocytes
requiresMonitoring blood pressure
liver function tests

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Sanofi hasBrand Aubagio